Video
Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC
Author(s):
In Partnership With:
John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
There have been interesting combinations performed with chemotherapy, androgen receptor (AR)-antagonists, and AR-pathway blocking agents in clinical trials, Araujo explains.
Therefore, it will be interesting to see the results with those combinations in the future, especially since radium-223 solely targets the bone — and its added benefits, if any, are still unknown. With such combination regimens, it could possible to improve survival in these patients by not only targeting bone metastases, but also metastases in the lungs and liver, he adds.
